Navigation Links
Benaroya Research Institute receives 7-year award to lead Immune Tolerance Network
Date:1/23/2014

(Seattle, January 23, 2014) The National Institutes of Health (NIH) has awarded Benaroya Research Institute at Virginia Mason (BRI) a 7-year grant to lead the Immune Tolerance Network (ITN). The award, totaling $27 million annually, supports efforts to develop, coordinate and implement international clinical trials conducted by the ITN to evaluate novel therapies for transplantation, allergy and autoimmune diseases.

The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of NIH. ITN clinical and laboratory investigators conduct studies at more than 250 clinical sites in the U.S., Canada, England, Australia and Mexico. The ITN is led by Gerald Nepom, M.D., Ph.D., who is also director of BRI.

"This grant award enables the ITN to facilitate collaborative studies between academic, governmental and industry researchers across the landscape of immunologic disease," Dr. Nepom said. "Through its unique ability to assemble and guide these collaborations, the ITN is able to develop cutting-edge clinical trials and mechanistic studies in immune tolerance that would not otherwise be conducted. BRI is proud to have been selected by the NIH to lead this effort."

In addition to selecting BRI to lead the ITN, the award will support teams of clinical investigators and laboratory scientists in the U.S. and abroad who are evaluating specific immunological therapies in clinical trials carefully designed and integrated with mechanistic studies. Examples include studies to discontinue immunosuppression therapy in patients who receive kidney or liver transplants; to understand how patients can tolerate transplanted organs without drugs, to test novel immunobiologic agents in psoriasis, multiple sclerosis, lupus and type 1 diabetes; and to improve allergy desensitization therapies or prevent food allergy.

BRI is an international leader in researching causes of and treatments for type 1 diabetes and a myriad of other immune system and autoimmune diseases. Both Massachusetts General Hospital and the University of California, San Francisco, the previous ITN headquarters, will partner with BRI to manage ITN operations.

"This significant grant award to BRI speaks to the caliber of research being conducted in the Washington life sciences community," said Chris Rivera, president and CEO of the Washington Biotechnology and Biomedical Association. "Advancing immune tolerance solutions through the ITN adds an exciting dimension to BRI's scientific leadership and provides hope for patients fighting immune-mediated diseases through BRI's focus on accelerating research discoveries into clinical therapies."

The ITN mission is to advance knowledge and develop clinical therapies that will direct the body's immune response toward repairing tissue damage and reversing and preventing disease. The immune system plays a vital role in keeping our bodies healthy and protected from infection. However, autoimmune diseases such as type 1 diabetes, multiple sclerosis and lupus, among others, result when the immune system aberrantly attacks the body's own cells. Allergies result when the immune system overreacts to a substance that is generally harmless. Following organ or tissue transplantation, the body's immune system rejects the transplanted tissue, requiring the use of immunosuppressive drugs. In all of these examples, the ITN strategy is to re-educate the immune system to learn to stop this dangerous response, and to recognize the affected tissue as its own.

The ITN is also a leading innovator in clinical trial transparency, as well as data and sample sharing, through TrialShare, an online resource that provides access to underlying data, analyses and samples from ITN's clinical trials. The ITN TrialShare web portal addresses a critical gap in data sharing, making information available from research studies to anyone, so that results from clinical trials are fully accessible to the public. This effort represents a major step forward addressing a widespread concern that data from many pharmaceutical clinical trials is often never fully disclosed, potentially putting patients at risk or requiring unnecessary duplication of studies.


'/>"/>

Contact: Kay Branz
kbranz@benaroyaresearch.org
206-342-6903
Immune Tolerance Network
Source:Eurekalert

Related medicine news :

1. Benaroya Research Institute announces $4.4 million grant for type 1 diabetes
2. Louisiana Tech University professor, researcher receives prestigious Humboldt Prize
3. FASEB announces 2014 Science Research Conference: Biology of the Immune System
4. HMS receives RPB Medical Student Eye Research Fellowship
5. IADR and Unilever partner to launch new behavioral research award
6. Air Force awards over $1 million to UC trauma researchers
7. UCLA researchers develop risk calculator to predict survival in heart failure patients
8. Mayo Clinic research finds risk of glaucoma blindness drops by half
9. Mount Sinai researchers find promising new drug targets for cocaine addiction
10. Researchers identify possible explanation for link between exercise & improved prostate cancer outcomes
11. Researchers awarded grant from the DeGregorio Family Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... ... 2017 , ... A new directory from the Senior Veterans ... connect elderly veterans of America's armed forces to a range of senior care ... on this year's increase in the Veterans Pension with Aid & Attendance for ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution provider ... 20 – 22 in San Francisco. As part of the Tri-Conference expo, which ... workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: Oncology™.” ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 2017  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... Vincent J. Angotti has been appointed ... company,s board of directors, effective Monday, March 6, ... experience leading executive and commercial teams at public ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications ... department visit are necessary for long-term opioid use to ... Feb. 16 th edition of The New ... "Emergency physicians see more patients in acute pain than ... Parker , MD, FACEP, president of the American College ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Function, Application, Cancer Type, Technology - Forecast to 2025" report ... ... grow at a CAGR of around 28.6% over the next decade ... Some of the prominent trends that the market is witnessing include ...
Breaking Medicine Technology: